Terlipressin Administration in Septic Shock Refractory to Catecholamines

Terlipressin Administration in Septic Shock Refractory to Catecholamines Bolus vs. Continuous Drip-Phase II

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00793559

Enrollment

Registered

2008-11-19

Start date

2008-11-30

Completion date

2009-07-31

Last updated

2008-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Septic Shock

Keywords

septic shock refractory to catecholamines

Brief summary

terlipressin is given to refractory septic shock patients who do not respond to noradrenalin in Israel and Europe. It is given by bolus injection. we attempt to investigate weather it is better to give it by continuous drip and avoid abrupt changes in BP and heart function

Interventions

DRUGterlipressin

1 mg of terlipressin one time only

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SUPPORTIVE_CARE

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Inclusion criteria

* septic shock patients receiving above 0.5 mcg/kg NA

Exclusion criteria

* allergy to terlipressin, CHF, IHD, pregnancy

Design outcomes

Primary

Measure	Time frame
CI, SVR,HR,BP, noradrenalin administration,renal function	6 mo

Countries

Israel

Contacts

Primary ContactTal Mann, Dr

tal_mb@hotmail.com97257345789

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026